Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis

Abstract

These data suggest that the location of metastatic sites significantly influences the diagnostic accuracy of ctDNA analysis in detecting EGFR mutations in NSCLC patients.

Liquid biopsy as a follow‐up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

“…Bone and adrenal glands metastases were more frequent among patients with detectable EGFR ‐activating mutations in cfDNA at baseline than among those without (bone, 56.5% vs 21.6%, P = .001; adrenal glands, 13.0% 6.0 vs 0.0%, P = .02) . These results are in line with a recent pooled analysis of 10 studies suggesting that metastatic site location influences the diagnostic accuracy of circulating tumor DNA (ctDNA) EGFR mutation testing in NSCLC with a higher sensitivity in patients with extrathoracic disease (M1b) versus pulmonary contralateral metastases or pleural/pericardial effusion (M1a) (odds ratio, 5.09; 95% CI, 2.93‐8.84) …”

Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy

“…55 These clinical findings are consistent with the evidence of higher sensitivity through any detection method in presence of higher number of metastases and metastatic sites. 56,57 On the contrary, previous data in a smaller Caucasian cohort showed that T790M was more common in biopsies of lung/pleura tissue and lymph nodes than in more distant sites. 48 One possible explanation is that tissue biopsy is more affected by tumor heterogeneity of metastatic sites compared with liquid biopsy.…”

<p>Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors</p>

“…In the study of Passiglia F,29 the location of metastatic sites significantly influences the diagnostic accuracy of ctDNA analysis, and the ability to identify resistant T790M mutations in the plasma of NSCLC patients is significantly higher in presence of extrathoracic disease (M1b) than the intrathoracic disease (M1a). In our study, 52 patients used ctDNA analysis in the detection of T790M mutations from plasma.…”